This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

Biotech Stock Mailbag: Rebounding From Hillary's Drug Tweet; Global Blood Weighs on Bluebird

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Clinton Drug Plan Cuts Market Exclusivity, Sets Mandatory R&D Spending

If Clinton's proposal is implemented, biotech companies would have less time to generate profits from their expensive biologic drugs before other companies could enter the market with cheaper copies.

Biotech Drug Stocks Tank After Clinton Tweet on Price Controls

The major biotech stock indices fell Monday minutes after Democratic presidential candidate Hillary Clinton tweeted that she'll release a plan to tackle escalating drug prices on Tuesday.

Biotech Stock Mailbag: Bristol, Exelixis, Lion Bio, GW Pharma

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Northwest Bio CEO: Brain Tumor Vaccine Study Enrollment Still Suspended

Slightly more than 300 out of a required 348 brain tumor patients are currently enrolled in Northwest Bio's DCVax-L phase III study.

Intra-Cellular Surges on Optimistic Outlook for Schizophrenia Drug

Schizophrenia patients treated with an experimental drug from Intra-Cellular Therapies reported fewer antipsychotic symptoms compared to a placebo in a large, phase III study, the company said Wednesday.

Amgen Adds Cholesterol-Lowering Pill to Pipeline With New Acquisition

Amgen is acquiring a privately held company developing a cholesterol-lowering pill just weeks after receiving approval for its own cholesterol-lowering injection.

Diarrhea Dings Xenoport Psoriasis Drug Study Results

An experimental pill from Xenoport reduced psoriasis skin symptoms significantly more than a placebo in a mid-stage study, but a high rate of diarrhea raises questions about the drug's future.

Tetraphase Executive Profits Hours Before Stock Plummets

A Tetraphase insider executed a well-timed insider stock sale right before the company's share price fell on negative clinical trial results.

Is FDA Having Trouble Setting Date for Biomarin, Sarepta Advisory Panels?

FDA missed a deadline earlier this week to finalize the Biomarin/Sarepta advisory panels on Nov. 23-24, if (and only if) Nov. 23-24 were the chosen dates.

Page 2 of 343
Top Rated Stocks Top Rated Funds Top Rated ETFs